Pacer Advisors
RVMD icon

Pacer Advisors’s Revolution Medicines RVMD Stock Holding History

Pacer Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,056
Closed -$41K – 2676
2024
Q2 		$41K Sell
1,056
-270
-20% -$10.1K ﹤0.01% 3263
2024
Q1 		$42.7K Buy
+1,326
New +$39.3K ﹤0.01% 3232
2021
Q2 		– Sell
-1,630
Closed -$75K – 1537
2021
Q1 		$75K Sell
1,630
-642
-28% -$28.8K ﹤0.01% 1345
2020
Q4 		$90K Buy
+2,272
New +$89.8K ﹤0.01% 1377

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pacer Advisors's RVMD Position: Q3 2024 in Review

Pacer Advisors sold out of Revolution Medicines (RVMD) in Q3 2024, closing a stake of 1,056 shares — an estimated $41K sold.

Pacer Advisors first reported a position in RVMD in Q4 2020 and held it in 4 quarters. The position peaked at $90K in Q4 2020. 255 funds tracked by Wall St. Rank hold RVMD as of Q3 2024.

  • Pacer Advisors reported no remaining Revolution Medicines position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 1,056 Revolution Medicines shares in Q3 2024, an estimated $41K.
  • Pacer Advisors first reported a position in Revolution Medicines in Q4 2020 and held it in 4 quarters.
  • Pacer Advisors's Revolution Medicines position peaked at $90K in Q4 2020.
  • 255 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.